Cambridge-based Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting in morning trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback